156 related articles for article (PubMed ID: 34862807)
1. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?
Megna M; Caiazzo G; Parisi M; Ruggiero A; Capasso G; Mascolo M; Russo D; Gallo L; Fabbrocini G; Napolitano M; Patruno C
Clin Exp Dermatol; 2022 May; 47(5):918-925. PubMed ID: 34862807
[TBL] [Abstract][Full Text] [Related]
2. Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: A case report.
Xiao Y; Peng S; Li X; Mao T; Fang M; Hu Y; Ye W
Medicine (Baltimore); 2023 Feb; 102(6):e32844. PubMed ID: 36820537
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor-associated dermatitis.
Cohen JN; Bowman S; Laszik ZG; North JP
J Am Acad Dermatol; 2020 Feb; 82(2):430-439. PubMed ID: 31859047
[TBL] [Abstract][Full Text] [Related]
4. Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature.
Caldarola G; Pirro F; Di Stefani A; Talamonti M; Galluzzo M; D'Adamio S; Magnano M; Bernardini N; Malagoli P; Bardazzi F; Potenza C; Bianchi L; Peris K; De Simone C
Expert Opin Biol Ther; 2020 Jun; 20(6):665-672. PubMed ID: 32045273
[No Abstract] [Full Text] [Related]
5. TNFα and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNFα antagonists.
Deubelbeiss C; Kolios AGA; Anzengruber F; French LE; Yawalkar N; Kempf W; Kerl K; Meier B; Navarini AA
J Cutan Pathol; 2018 Jan; 45(1):23-28. PubMed ID: 29023827
[TBL] [Abstract][Full Text] [Related]
6. A Case Series of Patients With Eczematous Eruptions Following IL-17 Inhibitor Treatment for Psoriasis Vulgaris.
Yousif J; Al-Dehneem R; Kaskas N; Gottlieb AB
J Drugs Dermatol; 2023 Dec; 22(12):1225-1227. PubMed ID: 38051861
[TBL] [Abstract][Full Text] [Related]
7. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis.
Res PC; Piskin G; de Boer OJ; van der Loos CM; Teeling P; Bos JD; Teunissen MB
PLoS One; 2010 Nov; 5(11):e14108. PubMed ID: 21124836
[TBL] [Abstract][Full Text] [Related]
8. Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients.
Włodarczyk M; Sobolewska A; Wójcik B; Loga K; Fichna J; Wiśniewska-Jarosińska M
World J Gastroenterol; 2014 Jun; 20(22):7019-26. PubMed ID: 24944497
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin.
Johansen C; Usher PA; Kjellerup RB; Lundsgaard D; Iversen L; Kragballe K
Br J Dermatol; 2009 Feb; 160(2):319-24. PubMed ID: 19016708
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-17A Drives IL-19 and IL-24 Expression in Skin Stromal Cells Regulating Keratinocyte Proliferation.
Xu X; Prens E; Florencia E; Leenen P; Boon L; Asmawidjaja P; Mus AM; Lubberts E
Front Immunol; 2021; 12():719562. PubMed ID: 34616394
[TBL] [Abstract][Full Text] [Related]
11. Comment on: 'Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?'.
Li M; Li W
Clin Exp Dermatol; 2022 Dec; 47(12):2305. PubMed ID: 36006173
[No Abstract] [Full Text] [Related]
12. Development of IL-17A inhibitor-induced atopic dermatitis-like rash in psoriasis patients: Insights into immune shift.
Li Q; Li X; Li W; Fan R; Ma Q; Luo X; Jian H; Chen X; Cao C; Zheng W
Exp Dermatol; 2024 Jan; 33(1):e14958. PubMed ID: 38009235
[TBL] [Abstract][Full Text] [Related]
13. Author reply to: Comment on: 'Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?'.
Ruggiero A; Megna M; Caiazzo G; Parisi M; Mascolo M; Russo D; Gallo L; Fabbrocini G; Napolitano M; Patruno C
Clin Exp Dermatol; 2023 Mar; 48(4):396-397. PubMed ID: 36631826
[No Abstract] [Full Text] [Related]
14. The role of IL-17 in psoriasis.
Malakouti M; Brown GE; Wang E; Koo J; Levin EC
J Dermatolog Treat; 2015 Feb; 26(1):41-4. PubMed ID: 24552504
[TBL] [Abstract][Full Text] [Related]
15. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F; Loesche C; Valentin MA; Jiang X; Cheng Y; Jarvis P; Peters T; Calonder C; Bruin G; Polus F; Aigner B; Lee DM; Bodenlenz M; Sinner F; Pieber TR; Patel DD
J Allergy Clin Immunol; 2017 Mar; 139(3):923-932.e8. PubMed ID: 27502297
[TBL] [Abstract][Full Text] [Related]
16. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
[TBL] [Abstract][Full Text] [Related]
17. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
18. Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways.
Tollenaere MAX; Hebsgaard J; Ewald DA; Lovato P; Garcet S; Li X; Pilger SD; Tiirikainen ML; Bertelsen M; Krueger JG; Norsgaard H
Br J Dermatol; 2021 Sep; 185(3):585-594. PubMed ID: 33792895
[TBL] [Abstract][Full Text] [Related]
19. Multi-omics segregate different transcriptomic impacts of anti-IL-17A blockade on type 17 T-cells and regulatory immune cells in psoriasis skin.
Kim J; Lee J; Li X; Kunjravia N; Rambhia D; Cueto I; Kim K; Chaparala V; Ko Y; Garcet S; Zhou W; Cao J; Krueger JG
Front Immunol; 2023; 14():1250504. PubMed ID: 37781383
[TBL] [Abstract][Full Text] [Related]
20. Psoriasis and other Th17-mediated skin diseases.
Tokura Y; Mori T; Hino R
J UOEH; 2010 Dec; 32(4):317-28. PubMed ID: 21226422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
